neotiv

Neotiv develops a digital platform featuring unique cognitive tests for early medical assessment and longitudinal follow-up of memory problems, particularly in Alzheimer's disease. It offers intuitive visual memory tasks for tracking performance, alongside customizable health questionnaires and neuropsychological evaluations. This flexible architecture supports research and healthcare applications, facilitating study configurations via a web portal and mobile app.

Co-founded by Dr. David Berron, Prof. Dr. med. Emrah Düzel, and Dr. Chris Rehse, neotiv leverages expertise in neuroscience, medicine, and technology. Their insight was to integrate rigorous cognitive testing with digital innovation. This foundation allows for accessible, precise methods to monitor memory health, advancing dementia research and improving patient care.

Neotiv's solutions support researchers in study designs and healthcare professionals for diagnosis and drug development. Globally utilized, the platform is validated by scientists for accuracy. The company envisions advancing Alzheimer's research and delivering patient-centered digital health solutions, aiming for seamless integration into medical procedures for safe, effective patient experiences.

Neotiv is a German digital‑health company that builds CE‑marked digital cognitive assessment tools and a cloud platform to screen for and monitor early memory impairment, primarily to detect and track Alzheimer’s‑related cognitive change in healthcare and research settings[5][1].

High‑Level Overview

• Mission: Neotiv aims to translate neuroscience into validated, scalable digital tools that enable early medical assessment and follow‑up of memory problems to improve Alzheimer’s detection and patient journeys[5][2].[2]
  - Investment philosophy / Key sectors / Impact on startup ecosystem: (Not applicable — neotiv is a portfolio/company rather than an investment firm; relevant investor news: neotiv raised a €10M Pre‑Series A to accelerate product rollout and internationalization[1].)
  - What product it builds: neotiv develops digital cognitive tests delivered via apps (neotivCare / neotivTrials) and an associated platform for remote, unsupervised cognitive assessment; the healthcare product neotivCare is CE‑marked as a medical device[5][2].[2]
  - Who it serves: primary users are healthcare systems (primary care physicians, specialists), patients, and clinical research teams running trials and population studies[2][4].[4]
  - What problem it solves: neotiv addresses the challenge of identifying early cognitive impairment and monitoring subtle cognitive change over time to enable earlier diagnosis, better trial recruitment, and outcome measurement in Alzheimer’s disease[4][2].[2]
  - Growth momentum: Founded in 2017, neotiv has commercial presence in German healthcare with a CE‑marked product and participated in large research consortia and national studies; it closed an expanded Pre‑Series A round (€10M) in 2022 to scale nationally and internationally, and continues to be adopted in clinical studies and consortia combining digital assessments with blood biomarkers[1][2][4].[1]

Origin Story

• Founding year and roots: neotiv was founded in 2017 as a spin‑off from Otto von Guericke University Magdeburg (OVGU) with close collaboration with the German Center for Neurodegenerative Diseases (DZNE)[1][5].[1]
  - Founders and background / how the idea emerged: The company was co‑founded by neuroscientists and clinicians (including CEO and co‑founder Dr. Chris Rehse and Chief Scientific Officer and co‑founder Dr. David Berron) to commercialize cognitive tests derived from recent brain‑research findings into deployable digital assessments[1][2].[2]
  - Early traction / pivotal moments: Early milestones include CE‑marking of neotivCare, adoption in German healthcare pathways, participation in large research efforts (for example integration into the Swedish REAL AD study and membership of the AD‑RIDDLE consortium), and securing €10M in Pre‑Series A financing to accelerate rollout and internationalization[1][4][2].[1]

Core Differentiators

• Science‑driven, research‑validated tests: Tests are derived from contemporary neuroscience and validated in collaborations with academic centers and national studies, which supports clinical applicability and trial use[4][2].[4]
  - Regulatory and healthcare readiness: neotivCare is CE‑marked as a medical device (risk class I) and meets digital health data‑protection requirements for use in German healthcare[1][2].[1]
  - Remote, unsupervised design: The platform and apps are built for remote, unsupervised administration, enabling frequent at‑home monitoring and scalable screening for large cohorts or primary‑care settings[2][5].[2]
  - Integration with biomarker efforts and trials: neotiv positions its digital cognitive measures to complement fluid (blood) biomarkers and serve as screening/monitoring tools in trials and population studies, improving early detection and outcome measurement[2][4].[2]
  - Commercial traction and funding: Institutional support and a €10M Pre‑Series A raise provide resources to expand supply in Germany and drive internationalization[1].[1]

Role in the Broader Tech Landscape

• Trend they are riding: neotiv sits at the intersection of digital therapeutics/diagnostics, remote health monitoring, and precision neurology — leveraging smartphone delivery and quantitative digital biomarkers to detect neurodegenerative disease earlier[5][4].[5]
  - Why timing matters: Advances in blood‑based biomarkers for Alzheimer’s and increased acceptance of remote digital assessment create a window where scalable digital cognitive testing can be combined with fluid biomarkers to enable population screening and more efficient trial recruitment[4][2].[4]
  - Market forces in their favor: Aging populations, regulatory pathways for digital medical devices in Europe, payer and provider interest in early detection, and rising investment into Alzheimer’s diagnostics/treatments increase demand for validated, low‑cost cognitive screening tools[1][4].[1]
  - Influence on ecosystem: By providing validated, deployable digital cognitive endpoints, neotiv can help standardize remote cognitive assessment in trials, accelerate recruitment and monitoring, and promote integration of digital tools into routine primary‑care pathways for cognitive health[2][4].[2]

Quick Take & Future Outlook

• What’s next: Expect continued internationalization of the neotivCare platform, deeper integration with blood‑biomarker workflows and large cohort studies, and broader adoption as a screening and monitoring tool in clinical trials and healthcare systems[1][2][4].[1]
  - Trends that will shape the journey: Wider availability of blood biomarkers for Alzheimer’s, reimbursement and regulatory clarity for digital diagnostics, and increasing clinician/patient comfort with remote testing will be key levers for growth[4][2].[4]
  - Potential influence evolution: If neotiv’s measures reliably predict pathology and track change, the company could become a standard digital cognitive endpoint for early‑stage Alzheimer’s detection and for monitoring therapeutic effects across trials and care pathways[4][2].[4]

Quick reiteration: neotiv is a science‑driven German digital‑health company (founded 2017) that builds CE‑marked, remote cognitive assessment apps and a cloud platform to enable earlier detection and monitoring of Alzheimer’s‑related cognitive decline, and has progressed from academic spin‑out to commercial and research adoption supported by institutional funding and consortium partnerships[5][1][2].[5]

If you’d like, I can:
- Summarize neotiv’s product features and study evidence in a one‑page brief; or
- Map their partnerships and competitors in digital cognitive assessment and Alzheimer’s biomarkers.